← Back to Search

Autologous Blood Patch for Lung Cancer

N/A
Waitlist Available
Led By Christopher Seder, MD
Research Sponsored by Rush University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients who underwent elective wedge resection, segmentectomy, lobectomy, or bilobectomy for suspected non-small cell lung cancer
Patients who have an air leak on the morning of postoperative Day 3
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 30 days
Awards & highlights

Study Summary

This trial examines whether ABP is effective in preventing a prolonged air leak after lung resection for cancer.

Who is the study for?
This trial is for adults over 18 who had lung cancer surgery and have an air leak on the third day after their operation. It's not for those who had more extensive surgeries like pneumonectomy, or women who are pregnant.Check my eligibility
What is being tested?
The study tests if using a patient's own blood to create a patch (ABP) can prevent leaks in the lungs after cancer surgery. Patients will either get this new treatment or the usual care, and researchers will compare how well each works.See study design
What are the potential side effects?
While specific side effects of ABP aren't detailed, it may include discomfort at the blood draw site, infection risk, and potential breathing issues related to procedure complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had surgery to remove part of my lung for suspected lung cancer.
Select...
I have an air leak from my surgery site on the third day after surgery.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
30-day Mortality
Hospital Length of Stay
In hospital mortality
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Autologous Blood PatchExperimental Treatment1 Intervention
Group II: Standard of Care (Per physician)Active Control1 Intervention

Find a Location

Who is running the clinical trial?

Rush University Medical CenterLead Sponsor
418 Previous Clinical Trials
162,439 Total Patients Enrolled
Christopher Seder, MDPrincipal InvestigatorRush University Medical Center
Sebastien Gilbert, MDStudy DirectorUniversity of Ottawa
3 Previous Clinical Trials
406 Total Patients Enrolled

Media Library

Autologous Blood Patch Clinical Trial Eligibility Overview. Trial Name: NCT04954625 — N/A
Lung Cancer Research Study Groups: Autologous Blood Patch, Standard of Care (Per physician)
Lung Cancer Clinical Trial 2023: Autologous Blood Patch Highlights & Side Effects. Trial Name: NCT04954625 — N/A
Autologous Blood Patch 2023 Treatment Timeline for Medical Study. Trial Name: NCT04954625 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it possible to register for this clinical investigation at the present time?

"Clinicaltrials.gov states that this research project is not admitting participants at the moment. The initial posting of this trial was on July 1st 2021 and it has been updated most recently on July 19th 2022, but there are 397 other active studies recruiting people as we speak."

Answered by AI
Recent research and studies
~20 spots leftby Jul 2025